Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Short report: Real-life analysis of the occurrence of persistent, transient, and fluctuating positive titres of neutralizing anti-drug antibodies in multiple sclerosis patients treated with interferon beta

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Serum and cerebrospinal fluid neurofilament levels predict longitudinal atrophy of the cervical spinal cord in progressive MS

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  3. Diagnostic value of oligoclonal bands in children: A Nationwide Population-Based Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • ABIRISK Consortium
Vis graf over relationer

Interferon beta (IFNβ) is a first line therapy for treatment of multiple sclerosis (MS). However, up to 47% of treated patients will develop neutralizing anti-drug antibodies (NAbs) against IFNβ, which at high titres can inhibit the therapeutic effect of the drug. This study aimed to determine the frequency of transient and fluctuating NAb positivity in a real-world clinical routine setting using a large retrospective international cohort of IFNβ-treated MS patients collected as a part of the ABIRISK consortium (n = 9657). Transient and fluctuating NAbs were rare (2.6% and 0.9%, respectively), but bring noteworthy considerations about clinical decisions in context of NAbs.

TidsskriftMultiple Sclerosis and Related Disorders
Sider (fra-til)103815
StatusE-pub ahead of print - 17 apr. 2022

Bibliografisk note

Copyright © 2022. Published by Elsevier B.V.

ID: 77930762